ThromboGenics' partner Alcon has launched Jetrea (ocriplasmin), the first and only medicine for the treatment of vitreomacular traction (VMT) in the UK.
Jetrea administered through a single intravitreal injection to treat VMT even when coupled with macular hole of diameter less than or equal to 400 microns.
ThromboGenics CEO Dr Patrik De Haes said the launch of Jetrea in Europe by Alcon so shortly after gaining European approval is testimony of the joint commitment to ensuring patients in Europe have access to this innovative drug as soon as possible.
"The additional €45 million payment from Alcon for reaching this milestone means we are well placed to continue investing in the commercialization of JETREA in the US via our own commercial organization," Dr Patrik De Haes added.
"We expect that Alcon will roll out JETREA into other European markets in the coming months and are working with our partner to ensure that all the support for physicians, payers and patients is fully in place."
The first sale of VMT therapy in EU triggers €45m milestone payment to ThromboGenics from Alcon, a division of Novartis.
Earlier Alcon made €45m milestone payment to ThromboGenics for gaining European approval for the VMT treatment.
At present, the National Institute for Health and Care Excellence (NICE) is conducting a single technology appraisal (STA) for Jetrea as part of the process to gain reimbursement when used by the UK National Health Service.